Cellzome strengthens management team
This article was originally published in Scrip
Executive Summary
Cellzome, a US drug discovery company focused on kinase-targeted treatments for inflammatory diseases, has appointed Dr Oliver Rausch senior director of biology and Dr Andrew Ratcliffe director of chemistry. Dr Rausch has 10 years' experience in the pharmaceutical industry, five of which were with UCB Celltech, most recently as director of biology. Dr Ratcliffe has drug discovery experience in inflammatory/respiratory diseases and has been with UCB Celltech for nine years, six of which were as associate director of medicinal chemistry. The appointments follow the announcement earlier this month of Cellzome's agreement with GlaxoSmithKline to develop therapies for inflammatory diseases.